Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2022 08 15T171656Z 1 LYNXMPEI7E0OB RTROPTP 4 HEALTH CORONAVIRUS BRITAIN
2022 08 15T171656Z 1 LYNXMPEI7E0OB RTROPTP 4 HEALTH CORONAVIRUS BRITAIN

UK to offer COVID booster to all adults from September


By Natalie Grover

LONDON (Reuters) -All adults in the United Kingdom will be offered a COVID-19 booster starting from September, health officials said, hours after the country became the first in the world to approve an Omicron-adapted shot.

The preference is to deploy what is known as a bivalent vaccine that targets both the original virus and the Omicron variant through the autumn campaign, but that will depend on the UK health regulator (MHRA) approving such shots and the state of vaccine supplies.

Previously, the UK’s Joint Committee on Vaccination and Immunisation (JCVI) had advised boosters https://www.reuters.com/world/uk/uk-weekly-covid-19-infections-rise-nearly-30-35-million-ons-2022-07-15 should be given to over 50s, individuals in clinical risk groups, frontline workers and care-home staff ahead of the winter, when respiratory viruses are typically at their peak.

Around 26 million people in Britain are estimated to be eligible for an autumn COVID-19 booster having had at least two COVID vaccine doses already, a UK Health Security Agency (UKHSA) spokesperson said.

On Monday, the MHRA gave Moderna’s bivalent shot conditional approval.

The endorsement of the vaccine is based on data that showed it produced a marginally better immune response against some Omicron https://www.reuters.com/world/uk/variant-adapted-covid-vaccine-wins-first-approval-britain-2022-08-15 variants, versus the original novel coronavirus – although whether that translates into stronger protection against serious disease is unclear.

UK contracts with Moderna and Pfizer-BioNTech – the partnership behind the other mRNA vaccine that has been tailored to also target Omicron – dictate that supply will switch to bivalent shots upon MHRA approval.

A UKHSA spokesperson declined to provide details on how much supply the country has of the Moderna bivalent shot.

“Where feasible, it would be preferable for a single type of booster vaccine to be offered throughout the duration of the autumn programme for simplicity of deployment,” the JCVI said in a statement on Monday.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

At the same time, the JCVI also advised that the original Moderna vaccine, the original Pfizer-BioNTech vaccine, and the Novavax shot – for certain patients – can be used in the autumn booster campaign.

“It is important that everyone who is eligible takes up a booster this autumn, whichever vaccine is on offer,” Wei Shen Lim, chair of COVID-19 immunisation on the JCVI, said in a statement.

LOST MOMENTUM

While the original COVID-19 vaccines continue to provide good protection against hospitalisation and death, vaccines have become less effective as the virus has evolved.

Britain was the first to approve COVID vaccinations in 2020, but has since lost momentum and is now in such a vulnerable position “any booster programme is to be warmly welcomed,” Danny Altmann, professor of immunology at Imperial College, London, told Reuters.

The debate about the nuances of which booster is tricky – the bivalent booster may offer some additional benefit against the BA.5 variant now dominant in Britain, although this may not be substantial, Altmann said.

“Still, the benefit coming into a difficult winter will be palpable if we can really encourage large-scale uptake,” he said.

In the week ending Aug. 5, more than 800 deaths were registered within 28 days of positive COVID test in England, data https://coronavirus.data.gov.uk published by the UK government showed.

(Reporting by Natalie Grover in London; editing by Barbara Lewis)

Recent Post: